Case Clinic Challenge: A 24-Year-Old Woman With A Recurrence of Bipolar Depression
Psychiatry
Curriculum:
Evidence-Based Therapies for Bipolar Depression: Making Informed Treatment Decisions
Evidence-Based Therapies for Bipolar Depression: Making Informed Treatment Decisions
Credits:
0.5 AMA PRA Category 1 Credit(s) ™
0.5 AMA PRA Category 1 Credit(s) ™
Launch Date:
November 23, 2015
November 23, 2015
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Psychiatrists, nurse practitioners, physician assistants, and other healthcare professionals working in a specialty setting who manage patients with bipolar depression.
Relevant Terms:
Bipolar Depression
Roger S. McIntyre, MD, FRCPC
Roger S. McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
University Health Network
Toronto, Ontario
Canada
Bio
Dr. Roger McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada.
Dr. McIntyre was named by Thomson Reuters in 2014 as one of “The World’s Most Influential Scientific Minds.” This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade.
Dr. McIntyre is involved in multiple research endeavours which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aim to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.
Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.
Dr. McIntyre is the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the CANMAT guidelines for the treatment of depressive disorders and bipolar disorders. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders.
| 1. | Construct individualized, evidence-based treatment plans for patients with bipolar I depression, assessing the data for approved and nonapproved therapies | 2. | Employ strategies for a patient-centric approach and more effective patient/caregiver communication with regard to treatment options, adherence, and improving outcomes and quality of life |
| 1. | Construct individualized, evidence-based treatment plans for patients with bipolar I depression, assessing the data for approved and nonapproved therapies |
| 2. | Employ strategies for a patient-centric approach and more effective patient/caregiver communication with regard to treatment options, adherence, and improving outcomes and quality of life |
Provided by Haymarket Medical Education
Supported by an educational grant from Sunovion Pharmaceuticals Inc.
Program Description
Patients with bipolar disorder spend more time in depression than mania or hypomania and tend to seek treatment during depressive episodes more often than during manic periods. There is often a discrepancy between real-world management of bipolar depression and evidence-based recommendations. Treating patients with bipolar depression ideally requires a partnership between the patient and the clinician, including shared decision-making. This interactive case highlights data-supported treatment options and effective patient dialogues that can help identify and respond to the patient’s individual needs and improve outcomes for bipolar depression.
Disclosure of Conflicts of Interest Statement
In accordance with the ACCME Standards for Commercial Support, Haymarket Medical Education requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Disclosures are as follows:
Roger S. McIntyre, MD, FRCPC: Advisory Boards: AstraZeneca, Bristol-Myers Squibb, France Foundation, GlaxoSmithKline, Janssen-Ortho Inc, Eli Lilly and Company, Lundbeck, Merck & Co., Organon, Pfizer, Shire. Speakers' Bureau: AstraZeneca, Janssen-Ortho Inc, Eli Lilly and Company, Lundbeck, Merck & Co., Pfizer. Research Grants: AstraZeneca, Janssen-Ortho Inc, Eli Lilly and Company, Lundbeck, Pfizer, Shire.
The staff, planners, and reviewer at Haymarket Medical Education have no relevant financial relationships to disclose.
Accreditation/Designation of Credit Statement
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only those credits commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. Sunovion Pharmaceuticals Inc. and HME do not recommend the use of any agent outside of the labeled indications.
Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Sunovion Pharmaceuticals Inc. and HME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.
Contact Information
If you have any questions relating to the accreditation of this activity, please contact Julie A. Tagliareni at julie.tagliareni@haymarketmedical.com.
In accordance with the ACCME Standards for Commercial Support, Haymarket Medical Education requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Disclosures are as follows:
Roger S. McIntyre, MD, FRCPC: Advisory Boards: AstraZeneca, Bristol-Myers Squibb, France Foundation, GlaxoSmithKline, Janssen-Ortho Inc, Eli Lilly and Company, Lundbeck, Merck & Co., Organon, Pfizer, Shire. Speakers' Bureau: AstraZeneca, Janssen-Ortho Inc, Eli Lilly and Company, Lundbeck, Merck & Co., Pfizer. Research Grants: AstraZeneca, Janssen-Ortho Inc, Eli Lilly and Company, Lundbeck, Pfizer, Shire.
The staff, planners, and reviewer at Haymarket Medical Education have no relevant financial relationships to disclose.
Accreditation/Designation of Credit Statement
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only those credits commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. Sunovion Pharmaceuticals Inc. and HME do not recommend the use of any agent outside of the labeled indications.
Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Sunovion Pharmaceuticals Inc. and HME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.
Contact Information
If you have any questions relating to the accreditation of this activity, please contact Julie A. Tagliareni at julie.tagliareni@haymarketmedical.com.
Privacy Policy
Mental Health Learning Center
http://www.mycme.com/mental-health-learning-center/section/5371/COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above |
© 2007-2024 HealthCourse, Inc. All rights reserved.
